CN119932188A - 用于前列腺癌检测和治疗的方法 - Google Patents

用于前列腺癌检测和治疗的方法 Download PDF

Info

Publication number
CN119932188A
CN119932188A CN202510096498.4A CN202510096498A CN119932188A CN 119932188 A CN119932188 A CN 119932188A CN 202510096498 A CN202510096498 A CN 202510096498A CN 119932188 A CN119932188 A CN 119932188A
Authority
CN
China
Prior art keywords
tmprss2
score
prostate cancer
therapy
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510096498.4A
Other languages
English (en)
Chinese (zh)
Inventor
I·M·莫林
M·基德
I·德罗斯多夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of CN119932188A publication Critical patent/CN119932188A/zh
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202510096498.4A 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法 Pending CN119932188A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
US62/633675 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment
CN201980027332.XA CN112673115B (zh) 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980027332.XA Division CN112673115B (zh) 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法

Publications (1)

Publication Number Publication Date
CN119932188A true CN119932188A (zh) 2025-05-06

Family

ID=65686083

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510096498.4A Pending CN119932188A (zh) 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法
CN201980027332.XA Active CN112673115B (zh) 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980027332.XA Active CN112673115B (zh) 2018-02-22 2019-02-21 用于前列腺癌检测和治疗的方法

Country Status (15)

Country Link
US (3) US11410748B2 (https=)
EP (2) EP3755816B1 (https=)
JP (2) JP7662337B2 (https=)
KR (2) KR102921718B1 (https=)
CN (2) CN119932188A (https=)
AU (2) AU2019224025B2 (https=)
BR (1) BR112020016989A2 (https=)
CA (1) CA3091647A1 (https=)
DK (1) DK3755816T3 (https=)
ES (1) ES3023842T3 (https=)
IL (1) IL276748A (https=)
MX (2) MX2020008702A (https=)
PL (1) PL3755816T3 (https=)
SG (1) SG11202007922XA (https=)
WO (1) WO2019165021A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
EP4100955A4 (en) * 2020-02-06 2024-02-28 Oncohost Ltd MACHINE LEARNING PREDICTION OF THERAPEUTIC RESPONSE
CA3227993A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4602184A1 (en) * 2022-10-12 2025-08-20 Liquid Biopsy Research LLC Methods for prostate cancer detection in saliva
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540852A (ja) * 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
MX338883B (es) * 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
CA2879557A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (en) * 2012-08-07 2016-04-20 Jackson H M Found Military Med PROSTATE CANCER GENE EXPRESSION PROFILE
US10431326B2 (en) * 2012-11-20 2019-10-01 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
CN105209636A (zh) * 2013-03-15 2015-12-30 麦塔马克基因股份有限公司 用于癌症预后的组合物和方法
EP3800266A1 (en) * 2013-06-13 2021-04-07 University Of South Australia Methods for detecting prostate cancer
AU2014305994B2 (en) * 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
AU2019224025A1 (en) 2020-09-10
SG11202007922XA (en) 2020-09-29
IL276748A (en) 2020-10-29
WO2019165021A1 (en) 2019-08-29
CN112673115A (zh) 2021-04-16
US20260066046A1 (en) 2026-03-05
JP2021514624A (ja) 2021-06-17
US20190259471A1 (en) 2019-08-22
KR20200123450A (ko) 2020-10-29
EP4538393A2 (en) 2025-04-16
MX2025000449A (es) 2025-03-07
PL3755816T3 (pl) 2025-06-30
JP2025096376A (ja) 2025-06-26
KR20260018206A (ko) 2026-02-06
JP7662337B2 (ja) 2025-04-15
CA3091647A1 (en) 2019-08-29
MX2020008702A (es) 2020-09-25
BR112020016989A2 (pt) 2020-12-29
KR102921718B1 (ko) 2026-02-03
AU2025238057A1 (en) 2025-11-27
EP3755816B1 (en) 2025-02-12
EP4538393A3 (en) 2025-07-02
EP3755816A1 (en) 2020-12-30
US11410748B2 (en) 2022-08-09
DK3755816T3 (da) 2025-04-28
CN112673115B (zh) 2025-02-18
US20230298695A1 (en) 2023-09-21
ES3023842T3 (en) 2025-06-03
AU2019224025B2 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
CN112673115B (zh) 用于前列腺癌检测和治疗的方法
US12305240B2 (en) Methods for colon cancer detection and treatment
US20240042069A1 (en) Predicting peptide receptor radiotherapy using a gene expression assay
HK40043345A (en) Methods for prostate cancer detection and treatment
HK40043345B (en) Methods for prostate cancer detection and treatment
HK40042084B (en) Methods for colon cancer detection and treatment monitoring
HK40042084A (en) Methods for colon cancer detection and treatment monitoring
HK40035975A (en) Predicting peptide receptor radiotherapy using a gene expression assay
HK40035975B (en) Predicting peptide receptor radiotherapy using a gene expression assay

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination